The association between BMI and BRAFV600E mutation may differ by primary tumor size.

IF 3.5 2区医学 Q2 ENDOCRINOLOGY & METABOLISM

European Thyroid Journal Pub Date : 2024-08-01 DOI:10.1530/ETJ-23-0255

Hyunju Park, Jung Heo, Hyun Jin Ryu, Min-Ji Kim, Young Lyun Oh, Tae Hyuk Kim, Sun Wook Kim, Jae Hoon Chung

{"title":"The association between BMI and BRAFV600E mutation may differ by primary tumor size.","authors":"Hyunju Park, Jung Heo, Hyun Jin Ryu, Min-Ji Kim, Young Lyun Oh, Tae Hyuk Kim, Sun Wook Kim, Jae Hoon Chung","doi":"10.1530/ETJ-23-0255","DOIUrl":null,"url":null,"abstract":"Objective: Previous reports suggest that a high body mass index (BMI) increases the risk of thyroid carcinoma. However, it remains unclear whether a high BMI is associated with the risk of BRAFV600E mutation. We aimed to assess whether a high BMI is associated with an increased risk of BRAFV600E mutation.Design and methods: We screened 6,558 PTC patients who had undergone BRAFV600E mutation testing between January 2009 and December 2017. After exclusion, 6,438 PTC patients were enrolled. We used logistic regression, and restricted cubic spline plots of the adjusted odd ratios (ORs) were illustrated to model the relationship between BMI and BRAFV600E mutation.Results: Among the 6,438 patients, 5,102 (79.2%) had the BRAFV600E mutation, and 4,954 (76.9%) were female. The median BMI was 23.8 (21.6 - 26.2) kg/m2. The primary tumor size was ≤ 1cm in 4,226 patients (65.6 %) and > 1cm in 2,212 patients (34.4 %). The BRAFV600E mutation was significantly associated with high BMI only in patients with primary tumor size > 1cm (OR 1.034; 95% CI 1.003 - 1.065; P = 0.029), whereas no clear association was found in patients with primary tumor size ≤ 1cm (OR 1.007; 95% CI 0.984 - 1.030; P = 0.570). Gender was not a significant factor in either group.Conclusions: Our study found that a higher BMI was positively associated with BRAFV600E mutation in patients with primary tumor size > 1cm. These results suggest that the association between BMI and BRAFV600E mutation status differs depending on primary tumor size.","PeriodicalId":12159,"journal":{"name":"European Thyroid Journal","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Thyroid Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1530/ETJ-23-0255","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Previous reports suggest that a high body mass index (BMI) increases the risk of thyroid carcinoma. However, it remains unclear whether a high BMI is associated with the risk of BRAFV600E mutation. We aimed to assess whether a high BMI is associated with an increased risk of BRAFV600E mutation.

Design and methods: We screened 6,558 PTC patients who had undergone BRAFV600E mutation testing between January 2009 and December 2017. After exclusion, 6,438 PTC patients were enrolled. We used logistic regression, and restricted cubic spline plots of the adjusted odd ratios (ORs) were illustrated to model the relationship between BMI and BRAFV600E mutation.

Results: Among the 6,438 patients, 5,102 (79.2%) had the BRAFV600E mutation, and 4,954 (76.9%) were female. The median BMI was 23.8 (21.6 - 26.2) kg/m2. The primary tumor size was ≤ 1cm in 4,226 patients (65.6 %) and > 1cm in 2,212 patients (34.4 %). The BRAFV600E mutation was significantly associated with high BMI only in patients with primary tumor size > 1cm (OR 1.034; 95% CI 1.003 - 1.065; P = 0.029), whereas no clear association was found in patients with primary tumor size ≤ 1cm (OR 1.007; 95% CI 0.984 - 1.030; P = 0.570). Gender was not a significant factor in either group.

Conclusions: Our study found that a higher BMI was positively associated with BRAFV600E mutation in patients with primary tumor size > 1cm. These results suggest that the association between BMI and BRAFV600E mutation status differs depending on primary tumor size.

查看原文本刊更多论文

BMI 与 BRAFV600E 基因突变之间的关系可能因原发性肿瘤大小而异。

目的：以前的报告表明，高体重指数（BMI）会增加罹患甲状腺癌的风险。然而，高体重指数是否与 BRAFV600E 基因突变的风险有关仍不清楚。我们旨在评估高体重指数是否与 BRAFV600E 突变风险增加有关：我们筛选了 2009 年 1 月至 2017 年 12 月间接受过 BRAFV600E 突变检测的 6558 名 PTC 患者。排除后，共纳入 6438 名 PTC 患者。我们采用了逻辑回归，并绘制了调整后奇数比（OR）的限制性立方样条图，以模拟BMI与BRAFV600E突变之间的关系：在6438名患者中，5102人（79.2%）有BRAFV600E突变，4954人（76.9%）为女性。体重指数中位数为 23.8 (21.6 - 26.2) kg/m2。4226名患者（65.6%）的原发肿瘤大小小于1厘米，2212名患者（34.4%）的原发肿瘤大小大于1厘米。BRAFV600E突变仅与原发肿瘤大小大于1厘米的患者的高体重指数显著相关（OR 1.034; 95% CI 1.003 - 1.065; P = 0.029），而与原发肿瘤大小小于1厘米的患者无明显关联（OR 1.007; 95% CI 0.984 - 1.030; P = 0.570）。结论：我们的研究发现，体重指数（BMI）越高，原发性肿瘤大小越小：我们的研究发现，在原发肿瘤大小大于 1 厘米的患者中，较高的体重指数与 BRAFV600E 基因突变呈正相关。这些结果表明，BMI与BRAFV600E突变状态之间的关系因原发肿瘤大小而异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Thyroid Journal Medicine-Endocrinology, Diabetes and Metabolism

CiteScore

6.70

自引率

2.10%

发文量

156

期刊介绍： The ''European Thyroid Journal'' publishes papers reporting original research in basic, translational and clinical thyroidology. Original contributions cover all aspects of the field, from molecular and cellular biology to immunology and biochemistry, from physiology to pathology, and from pediatric to adult thyroid diseases with a special focus on thyroid cancer. Readers also benefit from reviews by noted experts, which highlight especially active areas of current research. The journal will further publish formal guidelines in the field, produced and endorsed by the European Thyroid Association.

文献相关原料

公司名称	产品信息	采购帮参考价格